Biogen Pharmachem adopts FY26 financials, reappoints Bunkar at AGM

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Biogen Pharmachem Industries adopted audited financial statements for FY26 at its 31st AGM
  • Kelash Bunkar was reappointed as a director retiring by rotation
  • M/s. Goenka Mehta & Associates appointed as statutory auditors for the company
powered bylight_fuzz_icon
52235745

*this image is generated using AI for illustrative purposes only.

Biogen Pharmachem Industries Limited adopted its audited financial statements for the fiscal year ended March 31, 2026, during its 31st Annual General Meeting held on September 29, 2026. The meeting also saw the reappointment of Kelash Bunkar as a director and the appointment of new statutory auditors.

The Annual General Meeting was conducted via Video Conferencing and Other Audio Visual Means, commencing at 4:00 pm and concluding at 4:20 pm. This virtual format allowed shareholders to transact business remotely in compliance with regulatory norms.

Key resolutions passed

Shareholders approved three ordinary resolutions during the session:

  • Adoption of the audited financial statements for FY26, along with the reports of the Directors and Auditors.
  • Reappointment of Kelash Bunkar (DIN: 10911360) as a director retiring by rotation.
  • Appointment of M/s. Goenka Mehta & Associates Chartered Accountants, Rajkot (Firm Registration No: 129445W), as statutory auditors and fixation of their remuneration.

All businesses were transacted and passed by the shareholders present at the meeting. Details regarding the voting results, as required under Regulation 44(3) of the Listing Regulations, are being submitted separately to the stock exchange.

Historical Stock Returns for Biogen Pharmachem

1 Day5 Days1 Month6 Months1 Year5 Years
-3.57%0.0%-3.57%-40.00%-63.51%-49.06%

How might the appointment of Goenka Mehta & Associates influence Biogen Pharmachem's financial reporting standards and audit rigor in the upcoming fiscal year?

What specific strategic priorities will Kelash Bunkar focus on during his renewed directorship to drive the company's growth trajectory?

Will the adoption of the FY26 audited statements reveal any significant shifts in revenue composition or margin trends compared to previous years?

Biogen Pharmachem posts ₹85.95 lakh net profit in FY26, schedules AGM

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Biogen Pharmachem posted a net profit of ₹85.95 lakh in FY26, reversing a prior-year loss
  • Total revenue rose 113.5% to ₹255.80 lakh, driven by interest income and capital gains
  • The company scheduled its 31st AGM for September 29, 2026, via video conferencing
  • Paid-up capital increased to ₹90.26 crore following conversion of warrants to equity shares
powered bylight_fuzz_icon
50058759

*this image is generated using AI for illustrative purposes only.

Biogen Pharmachem Industries Limited reported a net profit of ₹85.95 lakh for the fiscal year ended March 31, 2026 (FY26), reversing a loss of ₹29.27 lakh in the previous year. The company has scheduled its 31st Annual General Meeting for Tuesday, September 29, 2026.

The entity, formerly known as Sun Techno Overseas Limited, generated total revenue of ₹255.80 lakh, derived entirely from other income as it had no operational revenue from its core business activities during the period.

Financial Performance

Biogen Pharmachem's financial results for FY26 highlight a shift to profitability driven by investment returns rather than operational turnover.

Metric FY26 FY25 Change
Total Revenue ₹255.80 lakh ₹119.77 lakh +113.5%
Net Profit ₹85.95 lakh -₹29.27 lakh Turnaround
Other Income ₹255.80 lakh ₹119.77 lakh +113.5%

Other income surged to ₹255.80 lakh from ₹119.77 lakh in FY25. This increase was primarily driven by interest income of ₹193.51 lakh and capital gains of ₹59.89 lakh. The company recorded total expenses of ₹160.13 lakh, including employee benefit expenses of ₹28.28 lakh and other expenses of ₹131.85 lakh.

Balance Sheet and Assets

As of March 31, 2026, the company's total assets stood at ₹9,939.89 lakh, an increase from ₹9,201.77 lakh in the prior year. Non-current assets comprised the majority of the balance sheet, with investments valued at ₹3,278.23 lakh and long-term loans and advances amounting to ₹6,612.97 lakh.

Cash and cash equivalents decreased significantly to ₹32.16 lakh from ₹201.63 lakh in FY25. This reduction reflects cash outflows for investments and long-term advances, partially offset by proceeds of ₹630.00 lakh from the conversion of preferential warrants into equity shares.

Capital Structure

The issued, subscribed, and paid-up capital increased to ₹90,26.03 lakh, divided into 90,26,03,000 equity shares of ₹1 each. This rise followed the allotment of 25,00,00,000 fully convertible warrants into equity shares on a preferential basis to the non-promoter group on April 15, 2025.

Promoter holding remained at 0%. Significant shareholders holding more than 5% include Interface Financial Services Limited (9.31%), Parichay Infrastructure Limited (8.59%), and Rama Shiva Lease Finance Private Limited (8.26%).

Corporate Governance and AGM Details

The 31st AGM will be held through Video Conferencing or Other Audio Visual Means. Shareholders will vote on ordinary business items, including:

  • Adoption of audited financial statements for FY26 along with Board and Auditor reports.
  • Reappointment of Kelash Bunkar as a director retiring by rotation.
  • Reappointment of M/s Goenka Mehta & Associates as statutory auditors until the AGM in 2031.

Remote e-voting will be available from Saturday, September 26, 2026, at 9:00 am to Monday, September 28, 2026, at 5:00 pm. The record date for voting rights is Tuesday, September 22, 2026.

What the Numbers Show

The company's profitability is entirely non-operational. With zero revenue from operations and total revenue comprising solely other income, the net profit of ₹85.95 lakh is driven by interest income and capital gains on investments. The significant drop in cash balances alongside an increase in long-term loans and investments suggests a strategic deployment of funds into financial assets rather than working capital for operational expansion.

Historical Stock Returns for Biogen Pharmachem

1 Day5 Days1 Month6 Months1 Year5 Years
-3.57%0.0%-3.57%-40.00%-63.51%-49.06%

What is Biogen Pharmachem's strategic roadmap for generating operational revenue, given its current reliance entirely on non-operational income?

How will the significant deployment of cash into long-term loans and advances impact the company's liquidity and ability to fund future business initiatives?

What are the specific terms and expected returns of the ₹6,612.97 lakh in long-term loans and advances that now dominate the balance sheet?

More News on Biogen Pharmachem

1 Year Returns:-63.51%